GMED Stock Price and Chart NYSE:GMED

gmed stock price

Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction. The medical-device maker’s revenue and earnings fell below Wall Street expectations. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.

gmed stock price

View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%. QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%.

GMED chart

Provides a general description of the business conducted by this company. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

In the last reported quarter, it posted an earnings surprise of 55.56%. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.

Globus Medical (GMED) Stock Forecast, Price & News

This medical device company designs and sells products that alleviate spine disorders. Globus Medical issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $2.30-$2.30 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of $1.13 billion-$1.13 billion, compared to the consensus revenue estimate of $1.12 billion. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Conversely, Globus Medical’s spine business is in a more balanced position amid the ongoing health crisis. The segment is gaining from product launches, competitive recruiting and pull-through from robotics. The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. Since then, GMED stock has decreased by 33.9% and is now trading at $49.10.

Galmed Pharmaceuticals stock price target cut to $9 from $24 at Maxim Group

11 brokers have issued 12 month price objectives for Globus Medical’s stock. On average, they anticipate the company’s share price to reach $69.75 in the next twelve months. This suggests a possible upside of 42.1% from the stock’s current price.

  • On average, they anticipate the company’s share price to reach $69.75 in the next twelve months.
  • The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.
  • David Demski has an approval rating of 61% among the company’s employees.
  • Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

The deal’s closing has brought together two major players in the growing musculoskeletal space currently valued at $50 billion. It combines Globus Medical’s and NuVasive’s complementary spine and orthopedic solutions and enabling technologies to create one of the industry’s most comprehensive, innovative offerings. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. The medical device maker reported second-quarter results that were much better than expected.

Zacks Mobile App

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. A recent stock price dip gives buy-and-hold investors an attractive entry price. The scores are based on the trading styles of Value, Growth, and Momentum.

Globus Medical (GMED) Q3 2022 Earnings Call Transcript – The Motley Fool

Globus Medical (GMED) Q3 2022 Earnings Call Transcript.

Posted: Tue, 08 Nov 2022 08:00:00 GMT [source]

Globus Medical saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 10,570,000 shares, an increase of 32.6% from the August 15th total of 7,970,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio is presently 6.8 days.

Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better. During second-quarter 2023, Globus Medical’s Musculoskeletal Solutions revenues were up 9.7% year over year.

Horizon Therapeutics Sees Positive Results in Tepezza Trial for Treatment of Thyroid Eye Disease

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. According to 12 analysts, the average rating for GMED stock is «Hold.» The 12-month stock price forecast is $67.5, which is an increase of 37.03% from the latest price. Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%.

There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. In the past year, GMED’s shares have declined 6.9% against the industry’s rise of 6.5%. Further, U.S. spine grew 6% in Q2 with notable gains across our product portfolio in biologics, MIS and pedicle screws, and 3D-printed implants.

Globus Medical Inc. (GMED Quick QuoteGMED – Free Report) recently announced that it has successfully closed the previously announced merger with NuVasive. The combined firm will offer one of the most extensive selections of musculoskeletal procedural solutions, enabling technology to influence the care continuum for surgeons and patients. One share of GMED stock can currently be purchased for approximately $49.10.

Here’s Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching – Simply Wall St

Here’s Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching.

Posted: Sun, 18 Jun 2023 07:00:00 GMT [source]

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis mother of accounting (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *